Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05279677
Other study ID # NCC3157
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date August 12, 2022
Est. completion date April 2024

Study information

Verified date March 2022
Source Chinese Academy of Medical Sciences
Contact Aiping Zhou, MD
Phone 86 13691161998
Email zhouap1825@126.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A single-arm, phase II study was designed to evaluate the efficacy and safety of fecal microbiota transplantation plus Sintilimab and Fruquintinib as the later line treatment in colorectal patients with advanced stages.


Description:

The combination of regorafenib plus nivolumab had already presented a manageable safety profile and encouraging antitumor activity in patients with mCRC as the REGONIVO trail reported. While additional investigations showed limited ORRs between 7%-33% as third or later line treatement in mCRC. Gut microbiota modulation, with the aim to reverse established microbial dysbiosis, is a novel strategy for the treatment of CRC. The individualized gut microbiome transplantation may further imrpove the efficacy of the combination therapy of CPI and TKI. Thus, a single-arm, phase II study was designed to evaluate the efficacy and safety of FMT plus Sintilimab and Fruquintinib as the later line treatment in CRC patients with advanced stages.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date April 2024
Est. primary completion date October 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Sign the informed consent form. - Metastatic or locally advanced colorectal adenocarcinoma unresectable or unfit for radical radiochemotherapy confirmed by pathology or cytology. - Microsatellite stable or pMMR patients failed standard treatment, including platinum, irinotecan, fluorouracil and Bevacizumab (Ras and BRAF wt patients should recived Cetuximab). - Patients have at least one lesion could be evaluated by RECIST v1.1 or mRECIST. - The Eastern Cooperative Oncology Group (ECOG) performance status score was 0 or 1. - The life expectancy is more than 3 months. - Good organ function: Blood routine: hemoglobin =90g/L, white blood cell =3.0×10^9/L, neutrophil =1.5×10^9/L, platelet =100×10^9/L; Renal function: creatinine=1.5×upper limit of normal (UNL) or creatinine clearance =60ml/min; Liver function: total bilirubin (TBIL)=1.5×upper limit of normal (UNL); ALT=2.5×UNL, AST=2.5×UNL, ALT=5×UNL and AST=5×UNL for patients with liver metastasis. Exclusion Criteria: - Have received any anti-PD-1, anti-PD-L1/L2 antibodies, anti-CTLA-4 antibodies and other immunotherapy in the past. - Have received any TKI therapy in the past. - Clinically significant ascites. - Known to have allergic reactions to any ingredients or excipients of experimental drugs. - Have received any antibiotics within 28 days before the first medication or any probiotics or prebiotics within 14 days before the first medication. - Radiotherapy, RFA, interventional therapy or surgery were performed within 28 days before the first medication (except for previous diagnostic biopsy). - Other active malignant tumors, excluding those who have been disease free for more than 5 years or in situ cancer considered to have been cured by adequate treatment. - Brain metastasis or meningeal metastasis has been confirmed. Patients with neurological symptoms should receive brain CT / MRI examination to exclude metastasis. - Patients who is suffering from intestinal obstruction, gastrointestinal bleeding, pulmonary fibrosis or interstitial pneumonia, renal failure, liver failure or cerebrovascular disease. - Diabetes was not controlled, defined as HbA1c > 7.5% after anti-diabetic drugs or hypertension was not controlled, defined as systolic / diastolic blood pressure > 140 / 90 mmHg after antihypertensive drug. - Myocardial infarction, severe/unstable angina, New York Heart Association (NYHA) class III or IV congestive heart failure in the past 12 months. - Known to be infected with human immunodeficiency virus (HIV), have acquired immunodeficiency syndrome (AIDS) related diseases, have active hepatitis B or hepatitis C. - Suffering from autoimmune diseases or history of organ transplantation requiring immunosuppressive therapy. - May increase the risk associated with participation in the study or administration of the study drug or mental illness that may interfere with the interpretation of research results. - Pregnant women (determined by serum human chorionic gonadotropin [hCG]) or lactating women, or plan to conceive during the treatment period, 2 months after cetuximab treatment and 6 months after capecitabine treatment. Women of childbearing age with positive or no pregnancy test at baseline. Women of childbearing age or sexually active men were not willing to use contraception during the study period, at least 2 months after cetuximab treatment and 6 months after capecitabine treatment. Postmenopausal women must be amenorrhea for at least 12 months to be considered infertile. - There are other serious diseases that the researchers believe patients cannot be included in the study

Study Design


Intervention

Drug:
Fecal microbiota transplantation plus Sintilimab and Fruquintinib
Microbiota capsules containing 1g gut microbiota, po d1-3 before anti-tumor treatment, total for 8 cycles. Sintilimab 200mg iv, q3w. Fruquintinib 5mg po d1-14, q3w.

Locations

Country Name City State
China National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing

Sponsors (1)

Lead Sponsor Collaborator
Chinese Academy of Medical Sciences

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary ORR Objective Response Rate Up to 2 years
Secondary OS Overall Survival Up to 2 years
Secondary PFS Progression Free Survival Up to 2 years
Secondary Adverse events Safety and tolerance Up to 2 years
See also
  Status Clinical Trial Phase
Recruiting NCT04712292 - Effects of COVID-19 Pandemic on the Outcomes of Colorectal Cancer
Active, not recruiting NCT03775980 - CIRSE Emprint Microwave Ablation Registry
Recruiting NCT05155124 - Safety of Cetuximab and Trifluridin Tipiracil as the Third-line Therapy in the RASwt mCRC Phase 1
Recruiting NCT06050447 - Factors Affecting the Results of Treatment of Patients With Colorectal Cancer
Active, not recruiting NCT03993626 - A Trial of CXD101 in Combination With Nivolumab in Patients With Metastatic Microsatellite-Stable Colorectal Cancer Phase 1/Phase 2
Recruiting NCT06314971 - Predicting Local and Distant Recurrence in T1 Colorectal Cancer
Recruiting NCT06342440 - Early Detection of Advanced Adenomas and Colorectal Cancer
Recruiting NCT05853094 - Postoperative Effects of Different Enterostomy Approaches N/A
Recruiting NCT06200831 - Simultaneous vs. Staged Resection of Colorectal Cancer With Synchronous Liver Metastases N/A
Recruiting NCT02758951 - Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases Phase 2/Phase 3
Recruiting NCT03686254 - The Effects of RFA in Combination With Second-line Chemotherapy and Bevacizumab on Unresectable CRLM Phase 2/Phase 3
Recruiting NCT05278351 - Tislelizumab Plus Cetuximab and Irinotecan vs Third-line Standard-of-care in Refractory mCRC Phase 2
Terminated NCT04873895 - TACE Plus Axitinib and Hydroxychlorquine for Liver-Dominant Metastatic Colorectal Cancer (CRC) Phase 1
Completed NCT04002128 - Tracheal Colonization and Outcome After Major Abdominal Cancer Surgery N/A
Recruiting NCT06208371 - Localized Treatment Versus Palliative Chemotherapy in CRC Patients With 10 or More CRLM Phase 3
Not yet recruiting NCT05129774 - Chemoradiotherapy Sequenced Radical Surgery for Colorectal Cancer With PALNM N/A
Completed NCT06410729 - Significance of Benign Lymph Node Enlargement in Colorectal Cancer
Completed NCT03507699 - Combined Immunotherapy and Radiosurgery for Metastatic Colorectal Cancer Phase 1
Active, not recruiting NCT03581890 - Socioeconomic Position in Acute Colorectal Cancer Surgery
Recruiting NCT05138094 - LIVACOR Trial: Minimally Invasive LIVer And Simultaneous COlorectal Resection N/A